{"id":"https://openalex.org/W1981064239","doi":"https://doi.org/10.1517/14740338.2015.1007040","title":"A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients","display_name":"A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients","publication_year":2015,"publication_date":"2015-02-07","ids":{"openalex":"https://openalex.org/W1981064239","doi":"https://doi.org/10.1517/14740338.2015.1007040","mag":"1981064239","pmid":"https://pubmed.ncbi.nlm.nih.gov/25659177"},"language":"en","primary_location":{"id":"doi:10.1517/14740338.2015.1007040","doi":"https://doi.org/10.1517/14740338.2015.1007040","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14740338.2015.1007040","pdf_url":null,"source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048482764","display_name":"Alana Dikopf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alana Dikopf","raw_affiliation_strings":["The University of Chicago Medicine, University of Chicago Medical Center , 5481 S. Maryland Ave, Chicago, IL 60637 , USA +1 773 702 4399 ; +1 773 834 1798 ; rsalgia@medicine.bsd.uchicago.edu","+1 773 834 1798","The University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA +1 773 702 4399"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago Medicine, University of Chicago Medical Center , 5481 S. Maryland Ave, Chicago, IL 60637 , USA +1 773 702 4399 ; +1 773 834 1798 ; rsalgia@medicine.bsd.uchicago.edu","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]},{"raw_affiliation_string":"+1 773 834 1798","institution_ids":[]},{"raw_affiliation_string":"The University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA +1 773 702 4399","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102383913","display_name":"Kevin Wood","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Wood","raw_affiliation_strings":["The University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA +1 773 702 4399; +1 773 834 1798; rsalgia@medicine.bsd.uchicago.edu","+1 773 834 1798","The University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA +1 773 702 4399"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA +1 773 702 4399; +1 773 834 1798; rsalgia@medicine.bsd.uchicago.edu","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]},{"raw_affiliation_string":"+1 773 834 1798","institution_ids":[]},{"raw_affiliation_string":"The University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA +1 773 702 4399","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003826371","display_name":"Ravi Salgia","orcid":"https://orcid.org/0000-0001-9643-7626","observed_orcids":["https://orcid.org/0000-0001-9643-7626"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ravi Salgia","raw_affiliation_strings":["The University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA +1 773 702 4399; +1 773 834 1798; rsalgia@medicine.bsd.uchicago.edu","+1 773 834 1798","The University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA +1 773 702 4399"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA +1 773 702 4399; +1 773 834 1798; rsalgia@medicine.bsd.uchicago.edu","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]},{"raw_affiliation_string":"+1 773 834 1798","institution_ids":[]},{"raw_affiliation_string":"The University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA +1 773 702 4399","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4745,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":{"value":0.41838272,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"14","issue":"3","first_page":"485","last_page":"493"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":1.0},{"id":"https://openalex.org/keywords/alk-positive-non-small-cell-lung-cancer","display_name":"ALK-positive non-small cell lung cancer","score":0.9340000152587891},{"id":"https://openalex.org/keywords/anaplastic-lymphoma-kinase","display_name":"anaplastic lymphoma kinase","score":0.8500000238418579},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8349999785423279},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7889999747276306},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9070000052452087},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9710000157356262},{"id":"https://openalex.org/keywords/ocular-toxicity","display_name":"ocular toxicity","score":0.8149999976158142},{"id":"https://openalex.org/keywords/gastrointestinal-toxicity","display_name":"gastrointestinal toxicity","score":0.7440000176429749},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.7739999890327454},{"id":"https://openalex.org/keywords/endocrine-toxicity","display_name":"endocrine toxicity","score":0.8190000057220459},{"id":"https://openalex.org/keywords/peripheral-edema","display_name":"peripheral edema","score":0.972000002861023},{"id":"https://openalex.org/keywords/alk-fusion-proteins","display_name":"ALK fusion proteins","score":0.6909999847412109},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6650000214576721}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9956316351890564},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8336672782897949},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.8314443826675415},{"id":"https://openalex.org/C2775999482","wikidata":"https://www.wikidata.org/wiki/Q18031208","display_name":"ROS1","level":4,"score":0.6670627593994141},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5540256500244141},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.5219190120697021},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.49140799045562744},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.4881947636604309},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4852895438671112},{"id":"https://openalex.org/C2779220645","wikidata":"https://www.wikidata.org/wiki/Q21099132","display_name":"Alectinib","level":5,"score":0.4771844148635864},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43089228868484497},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.34116846323013306},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3241831660270691},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2431851327419281},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.16603952646255493},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07200229167938232},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000077547","descriptor_name":"Crizotinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077548","descriptor_name":"Anaplastic Lymphoma Kinase","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020794","descriptor_name":"Receptor Protein-Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/14740338.2015.1007040","doi":"https://doi.org/10.1517/14740338.2015.1007040","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14740338.2015.1007040","pdf_url":null,"source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},{"id":"pmid:25659177","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25659177","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on drug safety","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W1513785617","https://openalex.org/W1969914656","https://openalex.org/W1970261657","https://openalex.org/W1974903221","https://openalex.org/W1977647793","https://openalex.org/W1981899028","https://openalex.org/W1989579159","https://openalex.org/W2000298456","https://openalex.org/W2010619956","https://openalex.org/W2021170035","https://openalex.org/W2049705687","https://openalex.org/W2050249255","https://openalex.org/W2053130096","https://openalex.org/W2055402151","https://openalex.org/W2067928178","https://openalex.org/W2070202276","https://openalex.org/W2080992857","https://openalex.org/W2081408143","https://openalex.org/W2082109642","https://openalex.org/W2096156234","https://openalex.org/W2097757428","https://openalex.org/W2101040581","https://openalex.org/W2123061084","https://openalex.org/W2134787029","https://openalex.org/W2136549983","https://openalex.org/W2147038864","https://openalex.org/W2150424194","https://openalex.org/W2153292904","https://openalex.org/W2154732538","https://openalex.org/W2169691338","https://openalex.org/W2257265893","https://openalex.org/W2418764371","https://openalex.org/W2463167950","https://openalex.org/W2480872124"],"related_works":["https://openalex.org/W2103633410","https://openalex.org/W2101040581","https://openalex.org/W2912870050","https://openalex.org/W2144539352","https://openalex.org/W2972079805","https://openalex.org/W2064658088","https://openalex.org/W2625797229","https://openalex.org/W2514723195","https://openalex.org/W2099440178","https://openalex.org/W2303165906"],"abstract_inverted_index":{"INTRODUCTION:":[0],"In":[1],"the":[2,5,13,21,87,171],"past":[3],"decade,":[4],"treatment":[6,80],"of":[7,15,36,66,122,163],"NSCLC":[8,58],"has":[9,29],"been":[10,30],"revolutionized":[11],"by":[12,176],"discovery":[14],"key":[16],"oncogenic":[17,67],"driver":[18],"mutations":[19],"and":[20,42,47,93,97,136,149,153,156,178,184],"therapies":[22],"that":[23,59,187],"specifically":[24],"target":[25],"these":[26,164],"mutations.":[27],"Crizotinib":[28,54],"shown":[31],"to":[32,101,106,170],"be":[33,138],"an":[34],"inhibitor":[35],"MET,":[37],"anaplastic":[38],"lymphoma":[39],"kinase":[40],"(ALK)":[41],"ROS1":[43],"receptor":[44],"tyrosine":[45,173],"kinases,":[46],"is":[48,55],"FDA":[49],"approved":[50],"for":[51,81,140],"ALK":[52,61,68,189],"inhibition.":[53],"effective":[56],"in":[57,64,114],"harbors":[60],"translocations":[62],"resulting":[63],"overexpression":[65],"fusion":[69],"proteins.":[70],"AREAS":[71],"COVERED:":[72],"This":[73],"paper":[74],"will":[75,85,179],"review":[76],"crizotinib":[77,109,132],"as":[78],"a":[79],"ALK-positive":[82,115],"NSCLC.":[83],"It":[84],"discuss":[86],"drug's":[88],"adverse":[89,126,145],"events,":[90],"drug-drug":[91],"interactions":[92],"other":[94],"important":[95],"clinical":[96],"safety":[98],"information":[99],"related":[100],"crizotinib.":[102],"EXPERT":[103],"OPINION:":[104],"Compared":[105],"standard":[107,134],"chemotherapy,":[108],"shows":[110],"improved":[111,120],"progression-free":[112],"survival":[113],"NSCLC,":[116],"with":[117,131,182],"patient's":[118],"reporting":[119],"quality":[121],"life.":[123],"However,":[124],"certain":[125],"events":[127,146],"are":[128,167],"more":[129,190],"frequent":[130],"versus":[133],"chemotherapy":[135],"must":[137],"monitored":[139],"closely.":[141],"The":[142],"most":[143],"common":[144],"include":[147],"ocular":[148],"gastrointestinal":[150],"disturbances,":[151],"cardiac":[152],"endocrine":[154],"abnormalities,":[155],"peripheral":[157],"edema.":[158],"Many,":[159],"though":[160],"not":[161],"all,":[162],"side":[165],"effects":[166],"likely":[168,180],"due":[169],"multiple":[172],"kinases":[174],"inhibited":[175],"crizotinib,":[177],"improve":[181],"second-":[183],"third-generation":[185],"inhibitors":[186],"inhibit":[188],"specifically.":[191]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":4},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2015,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}